“PRO-WAVE1: Monitoring patient reported outcomes (PROs) in prostate cancer through Wave Health,
a novel ePRO health platform” presents further findings on November 9
Lisbon, Portugal and El Segundo, CA – Joining top experts across various cancer fields, including oncology, radiology and urology, Wave Health has been selected for prestigious poster presentation at the 2024 European Multidisciplinary Congress on Urological Cancers (EMUC), focusing on showcasing the latest and most important breakthroughs and best practices in genito-urinary (GU) cancer treatment.
Treatment Technologies & Insights, Inc. (TTI) parent company of the globally recognized Wave Health digital health solution, 1 designed to help both patients and care teams better navigate and manage treatment, presents new findings from an 8-clinic study revealing critical symptom clusters to potentially inform multi-symptom treatment approaches. The novel new analysis of the PRO-WAVE1 real world evidence study data showcases symptom patterns impacting patients’ wellbeing and quality of life, including:
- Patient-reported symptoms, primarily sad feelings, pain and constipation, are identified as strongest predictors of diminished quality of life.
- Dynamic Time Warping (DTW) analysis identifies clusters of symptoms with similar severity progression.
- Visualizing symptom time series within clusters highlights co-occurring patterns with potential to guide targeted, multi-symptom treatment strategies.
“Because of the high patient compliance generated in this study, we had an exciting opportunity to analyze symptom clusters, showcasing the potential of the Wave Health platform to uncover clinically valuable insights into symptom patterns,” said TTI Data and Insights Lead, Hayden Hunskor. “Identifying and understanding these symptom clusters can help patients and healthcare providers better understand factors impacting quality of life and wellbeing. By tracking symptom connectivity over time, we can inform treatment plans and help patients more effectively manage issues simultaneously. This type of analysis opens a world of possibilities for further exploration and learning through longitudinal, holistic data.”
Previous study findings presented at ASCO conferences in the U.S. and Japan, and upcoming up at ISPOR in Barcelona, showed a rare 93% patient compliance, despite a majority of participants being older, less educated, and lacking tech confidence, alongside a 98% HCP perceived usefulness. Additionally, 78% of patients completed a feedback survey, with 90% expressing satisfaction with Wave Health for tracking activities and keeping their medical team informed, and 95% finding the information provided by the app “useful” for their treatment journey, underscoring its positive impact on health management.
Spain Study Background
In the “PRO-WAVE1: Monitoring patient reported outcomes (PROs) in prostate cancer through Wave Health, a novel ePRO health platform” study, patients engaged with the Wave Health App over a 13-week period. Patients used the app during treatment to complete a series of validated ePRO questionnaires, as well as a Weekly Symptom Review (WSR) assessing 16 Prostate cancer-specific symptoms, including the severity and/or frequency of each symptom. A report summary of the patients’ WSR was generated for care team to view in Wave Connect, a web-based platform – specifically for care team members to conduct weekly check-ins on patients, including verifying patient completion, evaluating report content, indicating plans for follow up with each patient, and rating their perceived value of the platform.
Dr. Ignacio Durán, primary investigator at Hospital Universitario Marqués de Valdecilla, noted that the platform enhances patient care, likely improving quality of life and survival. Dr. Estefania Linares from Hospital Universitario La Paz emphasized its practicality for overpopulated and rural hospitals, especially where patient visits are infrequent.
About the EMUC Congress
Being the only interdisciplinary event of its kind in Europe, EMUC24 identifies the best therapies, examines current practices, addresses controversies, and reviews emerging technologies. A diverse team of esteemed specialists provide their unique insights and expertise for a multi-faceted take on GU cancers. The EMUC24 congress is a collaboration of the European Society for Medical Oncology (ESMO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Association of Urology (EAU).
About Wave Health
Born from a personal cancer experience, Wave Health is a trusted digital health platform designed to transform the management and understanding of chronic conditions in large patient populations. It features a care portal and patient app that enhances engagement, compliance and personalized supported self-management while streamlining care workflows through automated communication and novel remote monitoring of patient reported data outside clinical settings. (in real-time and over the course of treatment). The platform generates actionable insights to drive patient engagement and adherence, to help medical teams manage individual treatments and identify emerging risks.
The Wave Health product has been created by TTI. The Spain study was financially supported by Bayer AG. In the UK,
Bayer has partnered with TTI as marketing agent for the prostate cancer version of Wave Health and is not responsible for the content or function of the product in any way.
1 Immunowave Study (Fred Hutchinson) – two abstract acceptances at ASCO 2023; PRO-WAVE1 Study (Spain) – poster presentation at ASCO GU 2024, abstract acceptance at ASCO 2024, poster presentation
at ASCO Breakthrough 2024
Lu, DJ, et al. “Evaluation of Mobile Health Applications to Track Patient-Reported Outcomes for Oncology Patients: A Systematic Review.” Adv Radiat Oncol. Jan-Feb. 2021.
Vercell, Amy, et al. “Patient-Facing Cancer Mobile Apps That Enable Patient Reported Outcome Data to Be Collected” International Journal of Medical Informatics, 25 Nov. 2022.
